In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 15_suppl ( 2013-05-20), p. e22078-e22078
Abstract:
e22078 Background: CTCs count at baseline and during treatment is an independent prognostic factor in metastatic colorectal cancer, while its role in early stages is still an open issue. No data are available in RC patients suitable for neoadjuvant chemoradiotherapy (CT-RT). Aim of the study: To investigate the role of CTCs in patients with locally advancedRC undergoing neo-adjuvant CT-RT. Methods: In a prospective single Institution study, cT3-4 and/or N+RC staged by rectal EUS and/or pelvic MRI and chest-abdomen CT scan, received capecitabine (825 mg/mq, orally, tid) with concurrent pelvic radiotherapy (50.4 Gy/28 fractions), followed by two cycles of intermittent capecitabine (1250 mg/mq, tid 14/21 days) and by low anterior resection or abdominopelvic resection with TME. Primary endpoints are evaluation of CTCs at baseline (t0), after CT-RT (t1), within 7 days after surgery (t2), and at 6-month from surgery (t3) and its correlation with main patient/tumor characteristics, CEA and response to neoadjuvant therapy. CTCs are enumerated with CellSearch System in 22.5 ml peripheral blood at over-mentioned time-points. A repeated measure analysis for binary outcome was used to evaluate changes in time of the percentage of patients with CTCs 〉 0. Results: 85/90 patients are evaluable: 52M/33F, median age 63 yrs (range 37-82); median follow up 25 months (range 6-52). At baseline (t0) 13 pts had 1 CTC (15.3%), two had 2 CTCs (2.4%) and one had 27 CTCs(1.2%) while in 69 cases (81.2%) no CTCs were detected. Information on CTCs was available for 67 patients at t1, 68 patients at t2 and 62 at t3. CTCs 〉 0 was reported on 16 (18.8%) at t0, 5 (7.5%) at t1, 6 (8.8%) at t2 and 3 (4.8% ) at t3 (P-value for trend: 0.039). CTCs at t0 was not statistically associated with any patient/tumor characteristics except for ultrasound T-stage that showed a trend CTCs (0% in uT2, 18.9% in uT3 and 40% in uT4, p-value 0.093), while no correlation with pCR was reported. Conclusions: CTCs count ≥ 1 was observed in 18.8% of patients with trend reduction over time probably due to therapy. Statistical correlation will be planned between CTCs and outcome.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2013.31.15_suppl.e22078
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2013
detail.hit.zdb_id:
2005181-5
Bookmarklink